LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Blood Cells Reprogram into Embryonic State
Biologics

Blood Cells Reprogram into Embryonic State

September 6, 2012 2 min read Premium comments

Advertisement

Blood Cells Reprogram into Embryonic State
Blook cells. Source: Wikimedia Commons and Gruff 15
Secondary

When is a blood cell not a blood cell?  When scientists from John Hopkins turn it into a stem cell that looks and behaves as it did when it was part of a 6-day-old embryo. Elias Zambidis, M.D., Ph.D., Assistant Professor of Oncology and Pediatrics at the Johns Hopkins Institute for Cell Engineering and the Kimmel Cancer Center, has coaxed adult blood cells to become induced-pluripotent stem cells (iPS)–adult cells reprogrammed to an embryonic-like state, and bearing unprecedented efficiencies.

Zambidis says his team has managed to develop a “super efficient, virus-free” way to make iPS cells. Generally, out of hundreds of blood cells, only one or two might turn into iPS cells. Using Zambidis’ method, 50-60% of blood cells can be engineered into iPS cells.

Zambidis’ team also found a way around the use of viruses to convert the cells to a stem cell state. Traditionally, scientists have used viruses to deliver a package of genes to cells to turn on processes that convert the cells from one type (such as skin or blood) back to stem cell states. However, viruses used in this way can mutate genes and initiate cancers in newly transformed cells. To insert the genes without using a virus, Zambidis’ team uses plasmids, rings of DNA that replicate briefly inside cells and then degrade. The blood cells were also stimulated with their natural bone-marrow environment.

Here is how they did it. The Johns Hopkins team took cord blood cells, treated them with growth factors, and used plasmids to transfer four genes into them. They then delivered an electrical pulse to the cells, making tiny holes in the surface through which the plasmids could slip inside. Once inside, the plasmids triggered the cells to revert to a more primitive cell state. The team then grew some of the treated cells in a dish alone, and some together with irradiated bone-marrow cells.

When scientists compared the cells grown using the blood cell method with iPS cells grown from hair cells and from skin cells, they found that the most superior iPS cells came from blood stem cells treated with just four genes and cultured with the bone marrow cells. These cells converted to a primitive stem cell state within 7 to 14 days. Their techniques also were successful in experiments with blood cells from adult bone marrow and from circulating blood.

How useful is all of this?  If this procedure is indeed an efficient method to produce virus-free iPS cells the researchers believe that it will speed research to develop stem cell therapies, using nearly all cell types, and may provide a more accurate picture of cell development and biology.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy